Newspaper Publication of Unaudited Financial Results for the Quarter Ended December 31, 2025
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals has submitted to BSE copies of newspaper clippings containing its unaudited financial results for Q3 FY26 and nine months ended December 31, 2025, published in Financial Express (English) and Punjabi Jagran (Punjabi) on February 14, 2026. On a standalone basis, total income from operations rose to Rs. 12,343.97 lakhs in Q3 FY26 from Rs. 8,440.72 lakhs in Q3 FY25, a jump of about 46%. Net profit after tax surged to Rs. 1,600.68 lakhs from Rs. 160.33 lakhs year-on-year, while basic EPS stood at Rs. 13.11 versus Rs. 2.42 in the same quarter last year. For nine months ended December 2025, total income reached Rs. 34,348.23 lakhs with net profit after tax of Rs. 4,205.55 lakhs, compared to Rs. 3,988.01 lakhs for the full year ended March 2025. Consolidated figures show similar strong growth, indicating a sharp turnaround in profitability.
Strong year-on-year revenue and profit growth in Q3 FY26 is a positive signal for shareholders, suggesting improving business momentum, though results remain unaudited and the stock may react to the headline numbers when markets digest them.